**Supplemental Table: Baseline Characteristics of Participants Evaluable for Primary Endpoint**

|  |  |  |
| --- | --- | --- |
|  | **Vitamin D**(n=73) | **Placebo**(n=64) |
| Median age, years (range) | 44.1 (27-49) | 45.0 (25-50) |
| Race, N (%) White Black Asian Native American Multi-Racial Unknown | 62 (85)5 (7)3 (4)1 (1)2 (3)0 | 58 (91)2 (3)2 (3)002 (3) |
| Hispanic, N (%) | 6 (8) | 6 (9) |
| Median body mass index, kg/m2 (range) | 24.9 (18.8-42.6) | 26.1 (19.8-44.9) |
| Breast cancer risk status, N (%)\* 5-year breast cancer risk ≥1.67% Lifetime breast cancer risk ≥20% Atypical hyperplasia/LCIS Prior stage 0-II breast cancer High mammographic density\*\* | 33 (45)19 (26)7 (10)4 (5)62 (85) | 29 (45)17 (27)12 (19)2 (3)53 (83) |
| Baseline serum 25(OH)D, N (%) <20 ng/mL 20-32 ng/mL | 22 (30)51 (70) | 21 (33)43 (67) |
| Baseline mammographic density, N (%) Scattered fibroglandular densities Heterogeneously/extremely dense | 11 (15)62 (85) | 11 (17)53 (83) |

**Abbreviations**: 25-hydroxyvitamin D (25(OH)D), lobular carcinoma *in situ* (LCIS)

\*Some women met multiple high-risk criteria.

\*\*Baseline mammogram with heterogeneously or extremely dense breasts.

24-month mammogram n=62

24-month mammogram n=69

12-month mammogram n=69

 -Analyzed for primary endpoint n=64

12-month blood n=65

12-month mammogram n=80

 -Analyzed for primary endpoint n=73

12-month blood n=69

6-month blood n=75

6-month blood n=83

Placebo n=105

Evaluable for toxicity n=102

Baseline mammogram n=69

Baseline blood n=88

Vitamin D n=103

Evaluable for toxicity n=102

Baseline mammogram n=76

Baseline blood n=90